Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Adalimumab, etanercept, infliximab, certolizumab pegol and golimumab for the treatment of rheumatoid arthritis not previously treated with conventional disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rheumatic drugs only (review of technology appraisal guidance 130, 186 and a part review of technology appraisal guidance 225)

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Abbott Laboratories (adalimumab) • Pfizer (etanercept) • Merck Sharp & Dohme Ltd (infliximab, golimumab) • UCB Pharma Ltd (certolizumab pegol) Patient/carer groups • Action on Pain • Afiya Trust • Arthritic Association • Arthritis & Musculoskeletal Alliance (ARMA) • Arthritis Care • Back Care • Black Health Agency • Counsel and Care • Disability Rights UK • Equalities National Council • Leonard Cheshire Disability • Muslim Council of Britain • Muslim Health Network • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • South Asian Health Foundation • Specialised Healthcare Alliance Professional groups	General • Allied Health Professionals • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Health Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium Possible comparator manufacturer(s) • Actavis UK (leflunomide) • Arrow Generics (azathioprine) • AstraZeneca UK (chloroquine) • Bristol Myers-Squibb (abatacept) • GlaxoSmithKline (azathioprine) • Hameln Pharmaceutical (methotrexate) • Hospira UK (methotrexate)

Consultees	**Commentators (no right to submit or appeal)**
• Association of Surgeons • Bone Research Society • British Association for Services to the Elderly • British Geriatrics Society • British Health Professionals in Rheumatology • British Institute of Musculoskeletal Medicine • British Institute of Radiology • British Orthopaedic Association • British Pain Society • British Society for Rehabilitation Medicine • British Society for Rheumatology • Physiotherapy Pain Association • Primary Care Rheumatology Society • Rheumatoid Arthritis Surgical Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association <u>Others</u> • Department of Health • Norfolk, and Great Yarmouth & Waveney PCT Cluster • Outer North East London PCT Cluster • Welsh Assembly Government	• Medac UK (leflunomide, methotrexate) • Mercury Pharma Group (methotrexate) • Mylan (azathioprine, sulfasalazine, penicillamine) • Novartis (ciclosporin) • Orion Pharma (UK) (methotrexate) • Pfizer (methotrexate, sulfasalazine, tofacitinib) • Roche (tocilizumab) • Sandoz (azathioprine, leflunomide, methotrexate) • Sanofi (hydroxychloroquine, leflunomide, sodium aurothiomalate) • Teva UK (azathioprine, leflunomide, methotrexate, penicillamine, sulfasalazine) • Zentiva UK (leflunomide) <u>Relevant research groups</u> • Arthritis Research UK • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People <u>Evidence Review Group</u> • School of Health and Related Research (ScHARR) • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • National Clinical Guideline Centre <u>Associated Public Health Groups</u> • tbc

Appendix C

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATOR

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.